Trial suggests metformin effective at reducing odds of serious outcomes for COVID-19 patients seeking early treatment

covid
Credit: Unsplash/CC0 Public Domain

In work published in the New England Journal of Medicine, researchers—led by the University of Minnesota Medical School and School of Public Health—have found that metformin, a commonly prescribed diabetes medication lowers the odds of emergency department visits, hospitalizations, or death due to COVID-19 by over 40 percent—and over 50 percent if prescribed early in onset of symptoms. The study also found no positive effect from treatment with either ivermectin or low-dose fluvoxamine.

"We are pleased to contribute to the body of knowledge around COVID-19 therapies in general, with treatments that are widely available," said Carolyn Bramante, MD, principal investigator of the study and an assistant professor of internal medicine and pediatrics at the U of M Medical School. "Our trial suggests that may reduce the likelihood of needing to go to the emergency room or be hospitalized for COVID-19."

Bramante noted that this was a secondary outcome of the trial; the primary outcome included whether someone had low oxygen on a home oxygen monitor, and none of the medications in the trial prevented the primary outcome.

The COVID-OUT trial was the nation's first to study whether , a medication for type 2 diabetes; low-dose fluvoxamine, an antidepressant; and ivermectin, an antiparasitic, or their combinations could serve as possible treatments to prevent ER visits or hospitalization, as well as Long-COVID.

The was simple—patients were randomly assigned to receive one of the three drugs individually, placebo, or a combination of metformin and fluvoxamine or metformin and ivermectin. Although the study was placebo-controlled with exact-matching placebo pills, Dr. Bramante says 83% of volunteers received medications supported by existing data because of the six-arm design. Each participant received 2 types of pills to keep their treatment assignment masked, for 3 to 14 days of treatment. Each volunteer tracked their symptoms, and after 14 days, they completed a survey.

Dr. Carolyn Bramante from the University of Minnesota answers questions about COVID OUT. Credit: University of Minnesota Medical School

The 1,323 participants in the trial were limited to adults with a greater than or equal to 25 kg/m2, which qualifies as overweight—for instance, someone who was at least five feet and six inches tall and weighed more than 155 pounds. To qualify for the study, volunteers enrolled within three days after receiving a positive COVID-19 test. It was among the first randomized clinical trials for COVID-19 to include pregnant women.

The study included those who were vaccinated and those who were not. This is the first published trial where the majority of participants were vaccinated.

"Although we know COVID-19 vaccines are highly effective, we know that some new strains of the virus may evade immunity and vaccines may not be available worldwide. So we felt we should study safe, available and inexpensive outpatient treatment options as soon as possible," said Bramante. "Understanding whether outpatient treatments could ensure more people survive the illness if they contract it and have fewer long-term symptoms is an important piece of the pandemic response."

The clinical trial launched in January 2021 after U of M Medical School researchers identified, through computer modeling and , that outpatient metformin use appeared to decrease the likelihood of mortality from, or being hospitalized for COVID-19. Their research, in partnership with UnitedHealth Group, was published in the Journal of Medical Virology and in The Lancet Healthy Longevity. Test-tube studies also found that metformin inhibited the COVID-19 virus in lab settings. These findings, along with additional prospective studies supporting the use of higher-dose fluvoxamine and ivermectin, provided the evidence to include all three medications as well as combination arms.

"Observational studies and in vitro experiments cannot be conclusive but do contribute to bodies of evidence," said Bramante, who is also an internist and pediatrician with M Health Fairview. "To complete this study, we enrolled volunteers nationwide through six institutions in the U.S., including in Minneapolis."


Explore further

Study finds no benefit to taking ivermectin for COVID-19 symptoms

More information: Carolyn T. Bramante et al, Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19, New England Journal of Medicine (2022). DOI: 10.1056/NEJMoa2201662

Carolyn T. Bramante et al, Outpatient metformin use is associated with reduced severity of COVID‐19 disease in adults with overweight or obesity, Journal of Medical Virology (2021). DOI: 10.1002/jmv.26873

Carolyn T Bramante et al, Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis, The Lancet Healthy Longevity (2020). DOI: 10.1016/S2666-7568(20)30033-7

Journal information: New England Journal of Medicine

Citation: Trial suggests metformin effective at reducing odds of serious outcomes for COVID-19 patients seeking early treatment (2022, August 18) retrieved 28 September 2022 from https://medicalxpress.com/news/2022-08-trial-metformin-effective-odds-outcomes.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
327 shares

Feedback to editors